|
業務類別
|
Biotechnology |
|
業務概覽
|
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA). |
| 公司地址
| 39 John F. Kennedy Street, 4th Floor, Cambridge, MA, USA, 02138 |
| 電話號碼
| +1 617 500-8880 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.apnimed.com |
| 員工數量
| 65 |
|
|
